Estrogenic protection against colorectal cancer development in obesity
雌激素对肥胖者预防结直肠癌的发展有保护作用
基本信息
- 批准号:10730681
- 负责人:
- 金额:$ 43.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-19 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AgeAgonistAnimal Cancer ModelAnimal ExperimentationAnimalsApoptosisApoptoticAttentionAzoxymethaneBioenergeticsBiologicalBody fatCancer BurdenCarcinogensCell Culture TechniquesCell Cycle ProgressionCell LineCell SurvivalCellsCellular AssayChronicColonColorectal CancerComputer AnalysisCytokine SignalingDataData SetDevelopmentDiagnosisEnergy MetabolismEnergy SupplyEnvironmentEnzyme-Linked Immunosorbent AssayEpitheliumEstradiolEstradiol ReceptorsEstrogen Receptor alphaEstrogen Receptor betaEstrogen ReceptorsEstrogen Replacement TherapyEstrogen ReplacementsEstrogen declineEstrogensEventExposure toFRAP1 geneFamilyFemaleFlow CytometryGene ExpressionGenesGonadal Steroid HormonesGonadal structureGrowthHCT116 CellsHT29 CellsHealthHigh Pressure Liquid ChromatographyHistologyHormonesHumanImpairmentIn VitroIncidenceInflammationInflammatoryInterleukin-6InterventionInvadedJAK2 geneKnowledgeLeptinLiteratureMAP Kinase GeneMalignant NeoplasmsMass Spectrum AnalysisMeasurementMeasuresMediatingMentorsMetabolicMetabolic PathwayMetabolismMitochondriaModelingModernizationMolecularMucous MembraneMusObesityOhioOncogenicOperative Surgical ProceduresOvariectomyOxidative PhosphorylationPIK3CG genePathogenesisPatientsPlayPostmenopausePremenopausePrevalencePrimary NeoplasmProliferatingPublic HealthQuantitative Reverse Transcriptase PCRRecording of previous eventsRegulationResearchResearch TechnicsRespiratory ChainRisk FactorsRoleSTAT3 geneSex DifferencesSignal PathwaySmall Interfering RNAStudentsTechniquesTestingThinnessTimeTissuesTransfectionTranslational ResearchTumor TissueUniversitiesWarburg EffectWestern BlottingWomanadipokinesanaerobic glycolysisbioinformatics toolcancer cellcancer typecell growthcollegecolon cancer cell linecolon tumorigenesiscolorectal cancer riskcytokinecytotoxicityepidemiology studyestrogenicexperimental studyhormone metabolismimprovedin vivoin vivo Modelmalemenmetabolomicsmouse modelpreventprogramsprotective effectsextumorigenesisundergraduate researchundergraduate student
项目摘要
Project Summary
Sporadic colorectal cancer (CRC), a subtype of CRC without family history but attributed to the presence of
various risk factors, is the majority (~75%) of new CRC cases in the US. Obesity and related chronic low-grade
inflammation are significant risk factors for sporadic CRC. Although obesity prevalence is higher in women than in men,
premenopausal women have lower incidences of CRC than age-matched men. Epidemiology studies have also indicated
that postmenopausal women increase their risks for CRC, but women with estrogen replacement therapies have a
substantially lower incidence in CRC. These observations suggest proinflammatory adipokines and cytokines associated
with obesity as oncogenic factors, whereas estrogen as a protecting factor in CRC development. However, how estrogen
suppresses adipokine- and cytokine-induced CRC pathogenesis is unclear. This knowledge gap is mainly because
adipokines/cytokines and estrogen have been studied as independent factors in separate studies, but their interaction has
not been explored in CRC. Additionally, although cancer cells have impaired mitochondrial metabolic function and
elevated anaerobic glycolysis (known as the Warburg effect), most research attention has been focused on studying the
underlying cellular and molecular mechanisms, without investigating the metabolic events involved. Further, a suitable
obesity-associated CRC animal model is needed to resemble the early histopathologic features leading to sporadic CRC
in humans. In this proposal, interaction between estrogen and adipokine leptin or cytokine IL-6 will be studied in in vitro
cell and in vivo mouse models to understand how estrogen protects against CRC development in obesity setting, via
opposing the oncogenic actions of leptin and IL-6 at cellular, molecular, metabolic, and functional levels. Additionally,
estrogen receptor β (ERβ) selective agonist and small interfering RNA transfection to ERβ that specifically reduces ERβ
expression will be used to explore estrogenic mechanism. Furthermore, cell lines originally obtained from primary
tumors of male and female patients and male and female mice with obesity-promoted colorectal tumorigenesis will be
included, considering sex as a biological variable. Findings of this study is invaluable for identifying sex-specific
biological targets for intervention to prevent and treat obesity-promoted CRC that would be different between men and
women. Importantly, this project provides plentiful opportunities to expose undergraduate students to a broad range of
modern techniques such as quantitative real-time PCR, flow cytometry and mass spectrometry, and have hands-on
participation in high-quality research using both in vitro and in vivo models. These activities will strengthen research
environment in cancer and metabolic research at Miami University, and facilitate collaborative research opportunities
involving students of different majors from different colleges at Miami University Ohio.
项目摘要
散发性结直肠癌(CRC)是一种无家族病史的结直肠癌的亚型,可归因于
各种危险因素,是美国新发结直肠癌病例的大多数(~75%)。肥胖与相关的慢性低度肥胖
炎症是散发性结直肠癌的重要危险因素。尽管女性的肥胖率高于男性,
绝经前女性的结直肠癌发病率低于同龄男性。流行病学研究也表明
绝经后妇女患CRC的风险增加,但接受雌激素替代治疗的妇女有
结直肠癌的发病率大大降低。这些观察表明,促炎脂肪因子和细胞因子与
肥胖是结直肠癌发生的致癌因素,而雌激素是结直肠癌发生的保护因素。然而,雌激素如何
抑制脂肪因子和细胞因子诱导的结直肠癌发病机制尚不清楚。这种知识鸿沟主要是因为
脂肪因子/细胞因子和雌激素在单独的研究中被作为独立的因素进行研究,但它们之间的相互作用
没有在CRC中探索过。此外,尽管癌细胞损害了线粒体代谢功能和
升高的厌氧糖酵解(称为Warburg效应),最受关注的研究一直集中在研究
潜在的细胞和分子机制,而不是研究涉及的代谢事件。此外,一个合适的
肥胖相关的结直肠癌动物模型需要类似于导致散发性结直肠癌的早期组织病理学特征
在人类身上。在这项建议中,雌激素与脂肪因子瘦素或细胞因子IL-6的相互作用将在体外进行研究。
细胞和活体小鼠模型,以了解雌激素如何通过以下途径防止肥胖环境中的结直肠癌
在细胞、分子、代谢和功能水平上反对瘦素和IL-6的致癌作用。另外,
雌激素受体β(ER-β)选择性激动剂和小干扰β对ER-β的特异性抑制作用
表达将被用来探索雌激素的机制。此外,最初从原代培养获得的细胞系
男性和女性患者的肿瘤和肥胖促进结直肠癌发生的男性和女性小鼠
包括在内,将性视为生物变量。这项研究的结果对于识别特定的性别是非常有价值的
干预预防和治疗肥胖促进的结直肠癌的生物靶点在男性和女性之间是不同的
女人。重要的是,这个项目提供了大量的机会让本科生接触到广泛的
实时定量聚合酶链式反应、流式细胞仪和质谱仪等现代技术,并亲身实践
参与使用体外和体内模型的高质量研究。这些活动将加强研究
迈阿密大学癌症和代谢研究的环境,并促进合作研究机会
涉及俄亥俄州迈阿密大学不同学院不同专业的学生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Haifei Shi其他文献
Haifei Shi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Haifei Shi', 18)}}的其他基金
Central Action of Brain-Derived Neurotrophic Factor in Male and Female Rats
脑源性神经营养因子在雄性和雌性大鼠中的中枢作用
- 批准号:
8956737 - 财政年份:2010
- 资助金额:
$ 43.35万 - 项目类别:
Central Action of Brain-Derived Neurotrophic Factor in Male and Female Rats
脑源性神经营养因子在雄性和雌性大鼠中的中枢作用
- 批准号:
8036830 - 财政年份:2010
- 资助金额:
$ 43.35万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 43.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 43.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 43.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)